Feasibility and Benefits of Reflexology in the Prevention of Neuropathy Induced by Oxaliplatin in Colorectal Cancer

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The management of colorectal cancer often requires oxaliplatin-based chemotherapy, either as part of curative treatment plans or exclusively in palliative situations. Oxaliplatin therefore plays a key role in the management of colorectal cancer. In addition to its digestive and hematological toxicity, oxaliplatin frequently induces chronic, often limiting, sensitive peripheral neuropathy. Only early discontinuation of oxaliplatin can limit the risk of clinically limiting neurotoxicity (grade ≥ 3). In oncology, managing the side-effects of treatment is an essential objective of supportive care, and is open to a variety of complementary medicines, including reflexology. This technique, derived from traditional Chinese medicine, involves stimulating reflex points on the arch of the foot.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age\>18 years treated for colorectal cancer in Digestive Oncology service Rangueil hospital

• Initiation of intravenous oxaliplatin chemotherapy at 85 mg/m² on a bimonthly schedule.

• Ability to understand and answer a self-questionnaire.

• Life expectancy egal or over 12 weeks

• Signed informed consent form

Locations
Other Locations
France
CHU de Toulouse
RECRUITING
Toulouse
Contact Information
Primary
Nadim FARES, MD
fares.n@chu-toulouse.fr
05 61 32 21 42
Time Frame
Start Date: 2024-04-29
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 40
Treatments
Experimental: Reflexology session
Patients included in the study and treated with oxaliplatin based regiment will receive 30-min of a standard reflexology session during each infusion for a maximum of 12 sessions over 6 months).
Related Therapeutic Areas
Sponsors
Leads: University Hospital, Toulouse

This content was sourced from clinicaltrials.gov